Hasty Briefsbeta

  • #Software Freedom
  • #FOSS
  • #Diabetes Management
  • The author was diagnosed with early-stage Type 2 Diabetes in March 2025.
  • A diabetes specialist recommended using a Continuous Glucose Monitor (CGM) and proprietary app, Freestyle Libre, which raised software freedom concerns.
  • The author refused to use the proprietary app due to restrictive terms and data collection policies.
  • Discovered a FOSS alternative, Juggluco, which worked effectively with the CGM device.
  • Juggluco provided better reporting features than the proprietary Abbott app, according to the specialist.
  • The author plans to contribute to Juggluco and help get it listed on F-Droid.
  • Abbott attempted to remove Juggluco from Google's Play Store, citing false claims about proprietary libraries.
  • The experience highlights the importance of software freedom in medical technology.
  • The author encourages support for SFC to continue this and other work in 2026.